4.7 Review

Depression, Antidepressants, and Neurogenesis: A Critical Reappraisal

Journal

NEUROPSYCHOPHARMACOLOGY
Volume 36, Issue 13, Pages 2589-2602

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/npp.2011.220

Keywords

neurogenesis; dentate gyrus; neurotrophic factors; stress; depression; antidepressant

Funding

  1. NIH
  2. Eli Lilly
  3. Lundbeck A/S
  4. Cyberonics
  5. Ortho-McNeil Janssen
  6. AstraZeneca
  7. Dainippon Sumitomo Pharma
  8. SK Life Sciences
  9. Sunovion Pharmaceuticals
  10. Agency for Healthcare Research and Quality (AHRQ)
  11. CeNeRx BioPharma
  12. PharmaNeuroBoost

Ask authors/readers for more resources

The neurogenesis hypothesis of depression posits (1) that neurogenesis in the subgranular zone of the dentate gyrus is regulated negatively by stressful experiences and positively by treatment with antidepressant drugs and (2) that alterations in the rate of neurogenesis play a fundamental role in the pathology and treatment of major depression. This hypothesis is supported by important experimental observations, but is challenged by equally compelling contradictory reports. This review summarizes the phenomenon of adult hippocampal neurogenesis, the initial and continued evidence leading to the development of the neurogenesis hypothesis of depression, and the recent studies that have disputed and/or qualified those findings, to conclude that it can be affected by stress and antidepressants under certain conditions, but that these effects do not appear in all cases of psychological stress, depression, and antidepressant treatment. Neuropsychopharmacology (2011) 36, 2589-2602; doi:10.1038/npp.2011.220; published online 21 September 2011

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available